Overview

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: An Open-Label, Multicenter, Single-Arm Phase IIa Clinical Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2030-07-16
Target enrollment:
Participant gender:
Summary
This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC). It is expected to investigate a novel therapeutic regimen with improved efficacy and enhanced safety for recurrent/metastatic NPC, thereby providing robust evidence-based medical support for the application of dual-target immune checkpoint inhibitors in nasopharyngeal carcinoma therapy
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University